Riluzole: Indication, Dosage, Side Effect, Precaution

Generic Medicine Info Full Generic Medicine Info

Dosage/Direction for Use Administration Contraindications Special Precautions Adverse Reactions Overdosage Drug Interactions Food Interaction Action Storage CIMS Class ATC Classification

This information is not country-specific. Please refer to the India prescribing information.

Generic Medicine Info

Administration

Should be taken on an empty stomach. Take on an empty stomach at least 1 hr before or 2 hr after meals.

Contraindications

Hepatic impairment (baseline transaminases >3 times the upper limit of normal).

Special Precautions

Patient with history of liver diseases. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, drowsiness or vertigo, if affected, do not drive or operate machinery. Monitoring Parameters Monitor serum aminotransferase concentrations (e.g. ALT) before and during therapy; signs and symptoms of hepatic injury.

Adverse Reactions

Significant: Neutropenia, dizziness, drowsiness, vertigo, interstitial lung disease. Cardiac disorders: Tachycardia. Gastrointestinal disorders: Oral paraesthesia, diarrhoea, abdominal pain, nausea, vomiting. General disorders and administration site conditions:Asthenia, pain. Immune system disorders:Angioedema, anaphylactoid reaction. Investigations: Abnormal LFT. Nervous system disorders: Headache.
Potentially Fatal: Hepatic injury.

Drug Interactions

Decreased rate of elimination with CYP1A2 inhibitors (e.g. caffeine, ciprofloxacin, oral contraceptives). Increased rate of elimination with CYP1A2 inducers (e.g. rifampicin, omeprazole). Increased risk of hepatotoxicity with hepatotoxic drugs (e.g. allopurinol, methyldopa, sulfasalazine).

CIMS Class

Neurodegenerative Disease Drugs

ATC Classification

N07XX02 - riluzole ; Belongs to the class of other nervous system drugs.

Disclaimer: This information is independently developed by CIMS based on riluzole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by CIMSAsia.com